Pfizer has agreed to buy oncology biotech Trillium Therapeutics in a deal worth about $2.3 billion (1.96bn) as the US drugmaker seeks to bolster its pipeline with a therapy it hopes will be transformative for blood cancers.
The pharmaceutical company will…

Click here to view the original article.